Praetorian Bio is delighted to welcome Alicia Solórzano, PhD, MBA, PMP, who has joined the company as Chief Development Officer. Alicia is a translational science leader with more than 20 years of experience advancing biopharmaceutical programs from discovery through first-in-human clinical development.
At Pfizer, Alicia led vaccine development programs and advanced innovative candidates through preclinical and clinical translation, while contributing to cross-functional development strategy and intellectual-property generation. She holds a PhD in Microbiology from the University of Salamanca and an MBA from West Texas A&M University.
Alicia joins as Praetorian Bio advances CaviStop®, its lead intranasal vaccine against dental caries, and a growing pipeline of first-in-class mucosal vaccines targeting the microbial drivers of oral disease. She will lead the development plan that takes our programs from the lab toward the clinic. Welcome to the team, Alicia.
